e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Clinical challenges in respiratory infection
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Frequency of side effects in antibiotic treatment for pneumonia
N. Hamao (Kyoto, Japan), I. Ito (Kyoto, Japan), S. Konishi (Kyoto, Japan), N. Tanabe (Kyoto, Japan), I. Oi (Kyoto, Japan), T. Hirai (Kyoto, Japan)
Source:
International Congress 2019 – Clinical challenges in respiratory infection
Session:
Clinical challenges in respiratory infection
Session type:
Thematic Poster
Number:
4552
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Hamao (Kyoto, Japan), I. Ito (Kyoto, Japan), S. Konishi (Kyoto, Japan), N. Tanabe (Kyoto, Japan), I. Oi (Kyoto, Japan), T. Hirai (Kyoto, Japan). Frequency of side effects in antibiotic treatment for pneumonia. 4552
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia
Source: Eur Respir J 2007; 30: 1234-1235
Year: 2007
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
Source: Eur Respir J 2006; 27: 158-164
Year: 2006
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
Frequency of antibiotic resistance and outcomes in severe community acquired pneumonia due to
Streptococcus pneumoniae
Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Year: 2009
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009
Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis
Source: Eur Respir J 2012; 39: 611-618
Year: 2012
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia
Source: Eur Respir J 2009; 33: 521
Year: 2009
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept